psalexa
logo

Amyotrophic Lateral Sclerosis Pipeline Analysis, 2017

Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: May 2017
Report Code: LS10963
Available Format:
Pages: 116

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

This report includes the Amyotrophic lateral sclerosis pipeline analysis as of May 2017, to estimate and analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, targets and mechanism of action, and drug origin with relevance to Amyotrophic lateral sclerosis.

Amyotrophic Lateral Sclerosis Pipeline Analysis

  • By Phase
    • Phase III
    • Phase II
    • Phase I
    • Pre-Clinical
    • Inactive
    • Discontinued
  • By Route of Administration
    • Oral
    • Intravenous
    • Not Disclosed
    • Others
  • By Molecule Type
    • Small Molecule
    • Protein
    • Monoclonal Antibody
    • Peptide
    • Others
  • By Company

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7000

Pre-Purchase Enquiry